{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:41:55Z","timestamp":1784950915310,"version":"3.55.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022MC098"],"award-info":[{"award-number":["ZR2022MC098"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018546","name":"Postdoctoral Innovation Project of Shandong Province","doi-asserted-by":"publisher","award":["SDCX-ZG-202400076"],"award-info":[{"award-number":["SDCX-ZG-202400076"]}],"id":[{"id":"10.13039\/501100018546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371181"],"award-info":[{"award-number":["32371181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117303","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:33:19Z","timestamp":1756913599000},"page":"117303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["G Protein-coupled receptors: key targets for maintaining the function of basal ganglia-thalamus-cortical circuits in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"242","author":[{"given":"Ji","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0005","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1093\/brain\/awad114","article-title":"Rigidity in Parkinson's disease: evidence from biomechanical and neurophysiological measures","volume":"146","author":"Asci","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson's disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-023-00600-z","article-title":"Translational molecular imaging and drug development in Parkinson's disease","volume":"18","author":"Haider","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2025.117303_b0020","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.bcp.2025.117303_b0030","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/mds.26712","article-title":"Unmasking levodopa resistance in Parkinson's disease","volume":"31","author":"Nonnekes","year":"2016","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.bcp.2025.117303_b0035","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cns.12165","article-title":"Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson's disease patients","volume":"19","author":"Yuan","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2025.117303_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114562","article-title":"Alterations in neurotransmitter co-release in Parkinson's disease","volume":"370","author":"Barcomb","year":"2023","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0045","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209704","article-title":"Neurotransmitters and Networks Interplay in Cognition and Gait Disturbances in patients with Parkinson Disease: beyond Lesion Localization","volume":"103","author":"Merino Ruiz","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2025.117303_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2024.101122","article-title":"Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease","volume":"73","author":"Reich","year":"2024","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.bcp.2025.117303_b0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.phrs.2017.01.008","article-title":"An update on the physiological and therapeutic relevance of GPCR oligomers","volume":"117","author":"Farran","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCRESAHA.124.323067","article-title":"G Protein-coupled Receptors: a Century of Research and Discovery","volume":"135","author":"Liu","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.117303_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1394516","article-title":"Exploring orphan GPCRs in neurodegenerative diseases","volume":"15","author":"\u00d6z-Arslan","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"7879","key":"10.1016\/j.bcp.2025.117303_b0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41586-021-03993-3","article-title":"The mouse cortico-basal ganglia-thalamic network","volume":"598","author":"Foster","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117303_b0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev-neuro-070918-050452","article-title":"Basal Ganglia Circuits for Action Specification","volume":"43","author":"Park","year":"2020","journal-title":"Annu. Rev. Neurosci."},{"issue":"13","key":"10.1016\/j.bcp.2025.117303_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110161","article-title":"Optogenetic activation of striatal D1R and D2R cells differentially engages downstream connected areas beyond the basal ganglia","volume":"37","author":"Grimm","year":"2021","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109847","article-title":"Direct and indirect pathway neurons in ventrolateral striatum differentially regulate licking movement and nigral responses","volume":"37","author":"Chen","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2025.117303_b0090","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46050","article-title":"Distinct roles of striatal direct and indirect pathways in value-based decision making","volume":"8","author":"Kwak","year":"2019","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2017.12.022","article-title":"Nucleus Accumbens Subnuclei Regulate Motivated Behavior via Direct Inhibition and Disinhibition of VTA Dopamine Subpopulations","volume":"97","author":"Yang","year":"2018","journal-title":"Neuron"},{"issue":"44","key":"10.1016\/j.bcp.2025.117303_b0100","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1523\/JNEUROSCI.1623-10.2010","article-title":"Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum","volume":"30","author":"Doig","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117303_b0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"issue":"7306","key":"10.1016\/j.bcp.2025.117303_b0110","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nature09159","article-title":"Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry","volume":"466","author":"Kravitz","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: a critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.41.8.707","article-title":"Baclofen in Parkinson's disease","volume":"41","author":"Lees","year":"1978","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0125","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41467-024-47552-6","article-title":"Neural signatures of indirect pathway activity during subthalamic stimulation in Parkinson's disease","volume":"15","author":"Steiner","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2009.11.002","article-title":"Oligomerization of G-protein-coupled receptors: a reality","volume":"10","author":"Ferr\u00e9","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0135","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/tp.2013.130","article-title":"The vital role of constitutive GPCR activity in the mesolimbic dopamine system","volume":"4","author":"Meye","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117303_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2012.07.015","article-title":"Dopamine D2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients","volume":"64","author":"Martorana","year":"2013","journal-title":"Neuropharmacology"},{"issue":"7695","key":"10.1016\/j.bcp.2025.117303_b0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature25758","article-title":"Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone","volume":"555","author":"Wang","year":"2018","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2025.117303_b0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","article-title":"Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome","volume":"160","author":"Yan","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/pharmrev.122.000618","article-title":"Dopamine, Immunity, and Disease","volume":"75","author":"Channer","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2025.117303_b0165","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/mds.28174","article-title":"Dopamine D1 Receptors Regulate Spines in Striatal Direct-Pathway and Indirect-Pathway Neurons","volume":"35","author":"Suarez","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2025.117303_b0170","first-page":"547","article-title":"Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats","volume":"10","author":"Song","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0175","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41593-022-01092-8","article-title":"Cerebellar dopamine D2 receptors regulate social behaviors","volume":"25","author":"Cutando","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2025.117303_b0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2016.06.007","article-title":"Current drug treatments targeting dopamine D3 receptor","volume":"165","author":"Leggio","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117303_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112925","article-title":"Lack of dopamine D4 receptor participation in mouse hyperdopaminergic locomotor response","volume":"396","author":"Liao","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117303_b0190","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s12272-010-1005-8","article-title":"Current perspectives on the selective regulation of dopamine D2 and D3 receptors","volume":"33","author":"Cho","year":"2010","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0195","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.pnpbp.2003.09.005","article-title":"The dopamine D4 receptors and mechanisms of antipsychotic atypicality","volume":"27","author":"Wong","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0200","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1111\/cns.14210","article-title":"Cortical dopamine D5 receptors regulate neuronal circuit oscillatory activity and memory in rats","volume":"29","author":"Albeely","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2025.117303_b0205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fncel.2018.00306","article-title":"Switching of the Microglial Activation Phenotype is a possible Treatment for Depression Disorder","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0210","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1161\/STROKEAHA.115.009792","article-title":"Activation of Dopamine D2 Receptor Suppresses Neuroinflammation through \u03b1B-crystalline by Inhibition of NF-\u03baB Nuclear Translocation in Experimental ICH mice Model","volume":"46","author":"Zhang","year":"2015","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0215","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11064-019-02730-7","article-title":"Dopamine Alters Lipopolysaccharide-Induced Nitric Oxide Production in Microglial Cells via Activation of D1-like Receptors","volume":"44","author":"Wang","year":"2019","journal-title":"Neurochem. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0220","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41593-022-01193-4","article-title":"Astrocytes mediate long-lasting synaptic regulation of ventral tegmental area dopamine neurons","volume":"25","author":"Requie","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"7435","key":"10.1016\/j.bcp.2025.117303_b0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature11748","article-title":"Suppression of neuroinflammation by astrocytic dopamine D2 receptors via \u03b1B-crystallin","volume":"494","author":"Shao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117303_b0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuroscience.2012.08.004","article-title":"Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice","volume":"223","author":"Rojas","year":"2012","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0235","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-020-14788-x","article-title":"Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0240","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1471-4159.2001.00619.x","article-title":"Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum","volume":"79","author":"Ishiwata","year":"2001","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0245","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2174\/1570159X21666230912093041","article-title":"Striatal Acetylcholine and Dopamine Interactions produce Situationappropriate Action selection","volume":"22","author":"Bradfield","year":"2024","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0250","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1038\/s41467-023-42311-5","article-title":"Acetylcholine waves and dopamine release in the striatum","volume":"14","author":"Matityahu","year":"2023","journal-title":"Nat. Commun."},{"issue":"6587","key":"10.1016\/j.bcp.2025.117303_b0255","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1126\/science.abn0532","article-title":"An action potential initiation mechanism in distal axons for the control of dopamine release","volume":"375","author":"Liu","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0260","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.121.261939","article-title":"Striatal Acetylcholine-Dopamine Imbalance in Parkinson Disease: InVivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET-Informed Correlational Tractography","volume":"63","author":"Sanchez-Catasus","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bcp.2025.117303_b0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fncir.2017.00110","article-title":"Dopamine and Acetylcholine, a Circuit Point of View in Parkinson's Disease","volume":"11","author":"Rizzi","year":"2017","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.bcp.2025.117303_b0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.102986","article-title":"Acetylcholine modulates prefrontal outcome coding during threat learning under uncertainty","volume":"13","author":"Tu","year":"2025","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002714","article-title":"Dopamine and acetylcholine have distinct roles in delay- and effort-based decision-making in humans","volume":"22","author":"Erfanian Abdoust","year":"2024","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2025.117303_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110092","article-title":"Ligand bias at the muscarinic acetylcholine receptor family: Opportunities and challenges","volume":"258","author":"Kaoullas","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117303_b0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2018.12.006","article-title":"The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice","volume":"361","author":"Meltzer","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0290","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1904338118","article-title":"Extrasynaptic acetylcholine signaling through a muscarinic receptor regulates cell migration","volume":"118","author":"Kato","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"47","key":"10.1016\/j.bcp.2025.117303_b0295","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp6301","article-title":"Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l-DOPA-induced dyskinetic behaviors","volume":"10","author":"Nielsen","year":"2024","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0300","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.neuron.2021.01.028","article-title":"Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments","volume":"109","author":"Cai","year":"2021","journal-title":"Neuron"},{"issue":"35","key":"10.1016\/j.bcp.2025.117303_b0305","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1523\/JNEUROSCI.0873-16.2016","article-title":"Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease","volume":"36","author":"Ztaou","year":"2016","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0310","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"issue":"10423","key":"10.1016\/j.bcp.2025.117303_b0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0320","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0189-20.2020","article-title":"Upregulation of nAChRs and changes in Excitability on VTA Dopamine and GABA Neurons Correlates to changes in Nicotine-Reward-Related Behavior","volume":"7","author":"Akers","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.bcp.2025.117303_b0325","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2014.02.005","article-title":"Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease","volume":"83","author":"Srinivasan","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"13","key":"10.1016\/j.bcp.2025.117303_b0330","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","article-title":"Modulatory effects of \u03b17 nAChRs on the immune system and its relevance for CNS disorders","volume":"73","author":"Kalkman","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2025.117303_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106711","article-title":"Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors","volume":"190","author":"Bono","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0340","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12974-016-0725-1","article-title":"Immunomodulatory effects of nicotine on interleukin 1\u03b2 activated human astrocytes and the role of cyclooxygenase 2 in the underlying mechanism","volume":"13","author":"Revathikumar","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"7937","key":"10.1016\/j.bcp.2025.117303_b0345","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41586-022-05407-4","article-title":"Locomotion activates PKA through dopamine and adenosine in striatal neurons","volume":"611","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117303_b0350","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1100\/tsw.2009.143","article-title":"Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway","volume":"9","author":"Quiroz","year":"2009","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0355","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.biopsych.2017.11.036","article-title":"Role of Striatal Direct Pathway 2-Arachidonoylglycerol Signaling in Sociability and Repetitive Behavior","volume":"84","author":"Shonesy","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117303_b0360","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/B978-0-12-801022-8.00005-2","article-title":"Adenosine receptors and dyskinesia in pathophysiology","volume":"119","author":"Tomiyama","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"issue":"44","key":"10.1016\/j.bcp.2025.117303_b0365","doi-asserted-by":"crossref","first-page":"15629","DOI":"10.1523\/JNEUROSCI.2526-11.2011","article-title":"Modulation of GABA transport by adenosine A1R-A2AR heteromers, which are coupled to both Gs- and G(i\/o)-proteins","volume":"31","author":"Crist\u00f3v\u00e3o-Ferreira","year":"2011","journal-title":"J. Neurosci."},{"issue":"6568","key":"10.1016\/j.bcp.2025.117303_b0370","doi-asserted-by":"crossref","DOI":"10.1126\/science.abk2055","article-title":"Convergence of adenosine and GABA signaling for synapse stabilization during development","volume":"374","author":"Gomez-Castro","year":"2021","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0375","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.tips.2018.10.007","article-title":"A2AR-D2R Heteroreceptor Complexes in Cocaine Reward and Addiction","volume":"39","author":"Borroto-Escuela","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2025.117303_b0380","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuropharm.2015.05.028","article-title":"Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer","volume":"104","author":"Ferr\u00e9","year":"2016","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0385","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/14728222.2014.981529","article-title":"Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease","volume":"19","author":"Fuxe","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"23","key":"10.1016\/j.bcp.2025.117303_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236100","article-title":"A2AR Transmembrane 2 Peptide Administration Disrupts the A2AR-A2AR Homoreceptor but not the A2AR-D2R Heteroreceptor complex: lack of Actions on Rodent Cocaine Self-Administration","volume":"20","author":"Borroto-Escuela","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117303_b0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pbb.2017.03.003","article-title":"Cocaine self-administration specifically increases A2AR-D2R and D2R-sigma1R heteroreceptor complexes in the rat nucleus accumbens shell. Relevance for cocaine use disorder","volume":"155","author":"Borroto-Escuela","year":"2017","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bcp.2025.117303_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154649","article-title":"Cordycepin improved the cognitive function through regulating adenosine A(2A) receptors in MPTP induced Parkinson's disease mice model","volume":"110","author":"Huang","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2025.117303_b0405","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuroscience.2016.02.035","article-title":"Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors","volume":"322","author":"Xu","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2025.117303_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105793","article-title":"A(2A)R antagonists triggered the AMPK\/m-TOR autophagic pathway to reverse the calcium-dependent cell damage in 6-OHDA induced model of PD","volume":"178","author":"Sophronea","year":"2024","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2025.117303_b0415","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroimage.2017.05.066","article-title":"Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia","volume":"157","author":"Zhou","year":"2017","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0420","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3233\/JAD-2010-090814","article-title":"Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment","volume":"20","author":"Arosio","year":"2010","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0425","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.7150\/ijbs.34211","article-title":"Caffeine Inhibits NLRP3 Inflammasome Activation by Suppressing MAPK\/NF-\u03baB and A2aR Signaling in LPS-Induced THP-1 Macrophages","volume":"15","author":"Zhao","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2025.117303_b0430","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12974-015-0333-5","article-title":"Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure","volume":"12","author":"Madeira","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021365","article-title":"\u03b1-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A(2A) Receptor Antagonist","volume":"24","author":"Cai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0440","first-page":"718","article-title":"Adenosine A2A Receptors Modulate \u03b1-Synuclein Aggregation and Toxicity","volume":"27","author":"Ferreira","year":"2017","journal-title":"Cereb. Cortex"},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0445","doi-asserted-by":"crossref","DOI":"10.3390\/biom13091350","article-title":"Functional Interaction between Adenosine A(2A) and mGlu(5) Receptors Mediates STEP Phosphatase Activation and Promotes STEP\/mGlu(5)R Binding in Mouse Hippocampus and neuroblastoma Cell Line","volume":"13","author":"Mallozzi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117303_b0450","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0455","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1523\/JNEUROSCI.2765-04.2005","article-title":"Gq\/11-induced and spontaneous waves of coordinated network activation in developing frontal cortex","volume":"25","author":"Calderon","year":"2005","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0460","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040864","article-title":"Group I mGluRs in Therapy and Diagnosis of Parkinson's Disease: Focus on mGluR5 Subtype","volume":"10","author":"Azam","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117303_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108275","article-title":"Targeting mGluR2\/3 for treatment of neurodegenerative and neuropsychiatric diseases","volume":"239","author":"Li","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117303_b0470","article-title":"Adolescent maturation of dorsolateral prefrontal cortex glutamate:GABA and cognitive function is supported by dopamine-related neurobiology","author":"Parr","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0475","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41398-021-01541-1","article-title":"Ventromedial prefrontal cortex\/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder","volume":"11","author":"Kantrowitz","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2025.117303_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104482","article-title":"Dopamine-glutamate neuron projections to the nucleus accumbens medial shell and behavioral switching","volume":"129","author":"Mingote","year":"2019","journal-title":"Neurochem. Int."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0485","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.neuropharm.2012.08.007","article-title":"Striatal interaction among dopamine, glutamate and ascorbate","volume":"63","author":"Morales","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.117303_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109698","article-title":"Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer","volume":"744","author":"Yang","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2025.117303_b0495","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fphar.2017.00812","article-title":"Shedding of Microvesicles from Microglia Contributes to the Effects Induced by Metabotropic Glutamate Receptor 5 Activation on Neuronal Death","volume":"8","author":"Beneventano","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117303_b0500","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuint.2019.03.020","article-title":"Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation","volume":"126","author":"Carvalho","year":"2019","journal-title":"Neurochem. Int."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0505","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071004","article-title":"Effect of the Metabotropic Glutamate Receptor Type 5 negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson's Disease","volume":"12","author":"Epping-Jordan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117303_b0510","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbb.2015.10.015","article-title":"The mGluR5 antagonist MPEP suppresses the expression and reinstatement, but not the acquisition, of the ethanol-conditioned place preference in mice","volume":"140","author":"Lee","year":"2016","journal-title":"Pharmacol. Biochem. Behav"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0515","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1085\/jgp.109.4.477","article-title":"Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK","volume":"109","author":"Sharon","year":"1997","journal-title":"Xenopus Oocytes. J Gen Physiol"},{"issue":"18","key":"10.1016\/j.bcp.2025.117303_b0520","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1523\/JNEUROSCI.4527-05.2006","article-title":"Regulation of nuclear factor kappaB in the hippocampus by group I metabotropic glutamate receptors","volume":"26","author":"O'Riordan","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2025.117303_b0525","doi-asserted-by":"crossref","unstructured":"Sanjay, et al., Nobiletin regulates intracellular Ca(2+) levels via IP(3)R and ameliorates neuroinflammation in A\u03b242-induced astrocytes. Redox Biol, 2024. 73: p. 103197.","DOI":"10.1016\/j.redox.2024.103197"},{"issue":"10","key":"10.1016\/j.bcp.2025.117303_b0530","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/bph.16010","article-title":"Histamine bidirectionally regulates the intrinsic excitability of parvalbumin-positive neurons in the lateral globus pallidus and promotes motor behaviour","volume":"180","author":"Qi","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.15692","article-title":"Central histaminergic signalling, neural excitability and epilepsy","volume":"179","author":"Yang","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-021-00545-z","article-title":"STN-ANT plasticity is crucial for the motor control in Parkinson's disease model","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0545","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s12035-015-9096-3","article-title":"Selective Modulation of Histaminergic Inputs on Projection Neurons of Cerebellum Rapidly Promotes Motor Coordination via HCN Channels","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113073","article-title":"Postsynaptic histamine H(3) receptors in ventral basal forebrain cholinergic neurons modulate contextual fear memory","volume":"42","author":"Zheng","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0555","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1046\/j.1471-4159.2002.00871.x","article-title":"Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy","volume":"81","author":"Rinne","year":"2002","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0560","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1471-4159.2000.0750540.x","article-title":"Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra","volume":"75","author":"Vizuete","year":"2000","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0565","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.neuropharm.2007.08.014","article-title":"Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats","volume":"53","author":"Liu","year":"2007","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0570","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pbb.2008.03.010","article-title":"Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist","volume":"90","author":"Liu","year":"2008","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bcp.2025.117303_b0575","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2017.02.039","article-title":"The roles of histamine and its receptor ligands in central nervous system disorders: an update","volume":"175","author":"Hu","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117303_b0580","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pbb.2014.12.002","article-title":"Doxepin and diphenhydramine increased non-rapid eye movement sleep through blockade of histamine H1 receptors","volume":"129","author":"Wang","year":"2015","journal-title":"Pharmacol. Biochem. Behav"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0585","doi-asserted-by":"crossref","first-page":"15899","DOI":"10.1038\/s41598-017-16019-8","article-title":"Histamine N-methyltransferase regulates aggression and the sleep-wake cycle","volume":"7","author":"Naganuma","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0590","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12974-016-0600-0","article-title":"Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation","volume":"13","author":"Rocha","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.bcp.2025.117303_b0595","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00210-019-01635-0","article-title":"Microglial histamine H(4)R in the pathophysiology of Parkinson's disease-a new actor on the stage?","volume":"392","author":"Schneider","year":"2019","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117303_b0600","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbi.2020.11.036","article-title":"Histamine-4 receptor antagonist ameliorates Parkinson-like pathology in the striatum","volume":"92","author":"Fang","year":"2021","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0605","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12035-022-03076-y","article-title":"Receptor and Ionic Mechanism of Histamine on Mouse Dorsolateral Striatal Neurons","volume":"60","author":"Peng","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"17","key":"10.1016\/j.bcp.2025.117303_b0610","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216247120","article-title":"Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus-thalamus circuitry","volume":"120","author":"Peng","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.10.016","article-title":"Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study","volume":"33","author":"Shan","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0620","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.115.230771","article-title":"Histamine H3 Receptor Regulates Sensorimotor Gating and Dopaminergic Signaling in the Striatum","volume":"357","author":"Kononoff Vanhanen","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0625","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41598-017-01453-5","article-title":"Activation of the ileal neuroendocrine tumor cell line P-STS by acetylcholine is amplified by histamine: role of H3R and H4R","volume":"7","author":"Pfanzagl","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0630","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071575","article-title":"Antagonism of Histamine H3 receptors Alleviates Pentylenetetrazole-Induced Kindling and Associated memory Deficits by Mitigating Oxidative stress, Central Neurotransmitters, and c-Fos Protein Expression in Rats","volume":"25","author":"Alachkar","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bcp.2025.117303_b0635","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00213-023-06339-1","article-title":"Chronic H(3)R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D(1)R mRNA expression in 6-hydroxydopamine-lesioned malerats","volume":"240","author":"Avila-Luna","year":"2023","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0640","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11302-018-9638-z","article-title":"Adenosine A(2A) and histamine H(3) receptors interact at the cAMP\/PKA pathway to modulate depolarization-evoked [(3)H]-GABA release from rat striato-pallidal terminals","volume":"15","author":"Morales-Figueroa","year":"2019","journal-title":"Purinergic Signal"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0645","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and Development of Tavapadon, a D1\/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0650","doi-asserted-by":"crossref","DOI":"10.3390\/biom13050829","article-title":"Dopamine D(1) Agonists: first potential Treatment for Late-Stage Parkinson's Disease","volume":"13","author":"Lewis","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0655","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1021\/acschemneuro.9b00589","article-title":"D1 Agonist improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects","volume":"11","author":"Young","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0660","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1021\/acs.jmedchem.1c01887","article-title":"Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor positive Allosteric Modulator with an improved Nonclinical Drug-Drug Interaction Risk Profile","volume":"65","author":"Hao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0665","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cpdd.874","article-title":"Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-positive Allosteric Modulator (D1PAM)","volume":"10","author":"Wilbraham","year":"2021","journal-title":"Healthy Subjects. Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0670","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cpdd.1039","article-title":"Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-positive Allosteric Modulator, in patients with Parkinson Disease","volume":"11","author":"Wilbraham","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.bcp.2025.117303_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121683","article-title":"Amelioration of oxidative stress utilizing nanoemulsion loaded with bromocriptine and glutathione for the management of Parkinson's disease","volume":"618","author":"Usama Ashhar","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0680","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mds.870080302","article-title":"Early combination therapy with bromocriptine and levodopa in Parkinson's disease","volume":"8","author":"Factor","year":"1993","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0685","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0690","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13105-011-0119-x","article-title":"The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease","volume":"68","author":"Ciobica","year":"2012","journal-title":"J. Physiol. Biochem."},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0695","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","article-title":"Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis","volume":"64","author":"Corvol","year":"2007","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0700","article-title":"Lisuride for levodopa-induced complications in Parkinson's disease","volume":"1999","author":"Clarke","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2025.117303_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102735","article-title":"Effects of Tiliroside and Lisuride Co-Treatment on the PI3K\/Akt Signal Pathway: Modulating Neuroinflammation and Apoptosis in Parkinson's Disease","volume":"11","author":"Alkholifi","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.bcp.2025.117303_b0710","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","article-title":"Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: a Systematic Review and Network Meta-Analysis","volume":"36","author":"Zhao","year":"2019","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0715","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","article-title":"Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials","volume":"33","author":"Kulisevsky","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.bcp.2025.117303_b0720","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijbiomac.2020.11.207","article-title":"Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment","volume":"167","author":"Nehal","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0725","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40263-020-00788-4","article-title":"Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: a Review of 12 Years' Clinical Experience","volume":"35","author":"Raeder","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2025.117303_b0730","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2022.11.012","article-title":"Effects of trihexyphenidyl on prefrontal executive function and spontaneous neural activity in patients with tremor-dominant Parkinson's disease: an fNIRS study","volume":"105","author":"Wang","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0735","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13311-013-0231-4","article-title":"Treatment of dystonia","volume":"11","author":"Thenganatt","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0740","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2024.4519","article-title":"An Acetylcholine M1 Receptor-positive Allosteric Modulator (TAK-071) in Parkinson Disease with Cognitive Impairment: a phase 2 Randomized Clinical Trial","volume":"82","author":"Shanbhag","year":"2025","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0745","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/npr2.12082","article-title":"A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects","volume":"40","author":"Ermer","year":"2020","journal-title":"Neuropsychopharmacol Rep"},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0750","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"10.1016\/j.bcp.2025.117303_b0755","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1021\/jm200290z","article-title":"Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators","volume":"54","author":"Hong","year":"2011","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2025.117303_b0760","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0091-3057(96)00354-1","article-title":"Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo","volume":"57","author":"Briggs","year":"1997","journal-title":"Pharmacol. Biochem. Behav"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0765","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1124\/jpet.106.101485","article-title":"N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine","volume":"317","author":"Zhang","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0770","first-page":"2287","article-title":"\u03b17\u2011nAchR agonist GTS\u201121 reduces radiation\u2011induced lung injury","volume":"40","author":"Mei","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117303_b0775","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0780","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ana.21348","article-title":"Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?","volume":"63","author":"Jankovic","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2025.117303_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120078","article-title":"Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: results from a multicenter, prospective, and open-label exploratory study in Japan","volume":"432","author":"Takahashi","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0790","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","article-title":"Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued","volume":"28","author":"Pinna","year":"2014","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0795","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0800","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/ene.15234","article-title":"Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease","volume":"29","author":"Wang","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"16","key":"10.1016\/j.bcp.2025.117303_b0805","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and Management of Dementia: Review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0810","first-page":"1611","article-title":"Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: a meta-analysis","volume":"17","author":"Meng","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0815","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-018-0162-2","article-title":"NMDA antagonists for treating the non-motor symptoms in Parkinson's disease","volume":"8","author":"Vanle","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0820","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389450013348489","article-title":"Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action","volume":"2","author":"Williams","year":"2001","journal-title":"Curr. Drug Targets"},{"issue":"4","key":"10.1016\/j.bcp.2025.117303_b0825","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0149-7634(96)00035-8","article-title":"Glutamate antagonists and Parkinson's disease: a review of clinical data","volume":"21","author":"Montastruc","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"21","key":"10.1016\/j.bcp.2025.117303_b0830","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1016\/j.bmc.2014.09.033","article-title":"AFQ056\/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization","volume":"22","author":"Vranesic","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0835","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0840","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/13543784.2014.931370","article-title":"Mavoglurant as a treatment for Parkinson's disease","volume":"23","author":"Petrov","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0845","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A Trial of the Novel mGluR5-negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2025.117303_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104807","article-title":"Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: an electrophysiological perspective","volume":"139","author":"Zheng","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2025.117303_b0855","doi-asserted-by":"crossref","first-page":"35320","DOI":"10.1038\/srep35320","article-title":"The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia","volume":"6","author":"Griebel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117303_b0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pbr.2021.06.003","article-title":"Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy","volume":"266","author":"Sharma","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.bcp.2025.117303_b0865","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbi.2018.11.006","article-title":"Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model","volume":"76","author":"Zhou","year":"2019","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.bcp.2025.117303_b0870","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/jpet.121.000719","article-title":"The Dopamine D1 Receptor positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived healthy Male Volunteers","volume":"380","author":"McCarthy","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0875","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0031-6997(25)06826-7","article-title":"Bromocriptine in Parkinson disease","volume":"37","author":"Lieberman","year":"1985","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2025.117303_b0880","doi-asserted-by":"crossref","unstructured":"Langtry, H.D. and S.P. Clissold, Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs, 1990. 39(3): p. 491-506.","DOI":"10.2165\/00003495-199039030-00009"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0885","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/0023210-200923010-00006","article-title":"Ropinirole prolonged release: in advanced Parkinson's disease","volume":"23","author":"Weber","year":"2009","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0890","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","article-title":"Rotigotine Transdermal Patch: a Review in Parkinson's Disease","volume":"33","author":"Frampton","year":"2019","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0895","article-title":"Trihexyphenidyl for dystonia in cerebral palsy","volume":"5","author":"Harvey","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2025.117303_b0900","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M(1) positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0905","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41598-018-38305-9","article-title":"Phencynonate S-isomer as a eutomer is a novel central anticholinergic drug for anti-motion sickness","volume":"9","author":"Xu","year":"2019","journal-title":"Sci. Rep."},{"issue":"Suppl","key":"10.1016\/j.bcp.2025.117303_b0910","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1002\/ana.410160716","article-title":"Calmodulin systems in neuronal excitability: a molecular approach to epilepsy","volume":"16","author":"DeLorenzo","year":"1984","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0915","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0006-3223(01)01093-9","article-title":"Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA\/2 mice","volume":"50","author":"Simosky","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2025.117303_b0920","doi-asserted-by":"crossref","first-page":"543","DOI":"10.18632\/aging.102640","article-title":"Activation of \u03b17 nAChR by PNU-282987 improves synaptic and cognitive functions through restoring the expression of synaptic-associated proteins and the CaM-CaMKII-CREB signaling pathway","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"21","key":"10.1016\/j.bcp.2025.117303_b0925","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.1021\/jm3006542","article-title":"Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective \u03b14\u03b22 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders","volume":"55","author":"Mazurov","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2025.117303_b0930","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","article-title":"Istradefylline, an adenosine a2a receptor antagonist, for patients with Parkinson's Disease: a meta-analysis","volume":"324","author":"Chen","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0935","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1474-4422(21)00356-2","article-title":"Amantadine: an old drug reborn","volume":"20","author":"Pahwa","year":"2021","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117303_b0940","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/acs.jmedchem.0c01912","article-title":"Ifenprodil Stereoisomers: Synthesis, absolute Configuration, and Correlation with Biological activity","volume":"64","author":"Bechthold","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117303_b0945","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s10072-021-05319-7","article-title":"Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis","volume":"42","author":"Negida","year":"2021","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2025.117303_b0950","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.bcp.2025.117303_b0955","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1124\/dmd.117.077552","article-title":"Species-specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu(5)-negative Allosteric Modulator VU0424238 (Auglurant)","volume":"45","author":"Crouch","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2025.117303_b0960","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s43440-024-00675-5","article-title":"LY354740, an agonist of glutamatergic metabotropic receptor mGlu(2\/3) increases the cytochrome P450 2D (CYP2D) activity in the frontal cortical area of rat brain","volume":"76","author":"Bromek","year":"2024","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117303_b0965","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.5664\/jcsm.9328","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of sleep Medicine clinical practice guideline","volume":"17","author":"Maski","year":"2021","journal-title":"J. Clin. Sleep Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:17:04Z","timestamp":1761455824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":193,"alternative-id":["S0006295225005684"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117303","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G Protein-coupled receptors: key targets for maintaining the function of basal ganglia-thalamus-cortical circuits in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117303"}}